This live panel discussion is part of the AI Happy Hour series, brought to you by Stanford AIMI and friends. We cover hot topics in AI in medicine as well as live questions & comments from attendees. It's casual, insightful, and open to all!

Stanford AIMI: aimi.stanford.edu/
Twitter: twitter.com/StanfordAIMI


Panelists:
Andrea de Souza, Sr. Director, Research Data Sciences & Engineering - Eli Lilly and Company
Judy Gichoya, MD, MS - Emory
Maureen Hillenmeyer, PhD, Founder & CEO - Hexagon Bio
Faisal M. Khan, PhD - AstraZeneca
Matthew Lungren, MD, MPH - Stanford
Anna Bauer-Mehren, PhD - Roche
Maliheh Poorfarhani, Global Sourcing Director - Bayer
Sharon Zhou, PhD Computer Science - Stanford


Outline:
00:00​ - AI Happy Hour Theme Song (Composed by Dr. Hugh Harvey)
4:47 Introduction to Panel
12:34 Examples of AI in Pharma - Real world prognostic and efficacy data, drug structure modeling, shipping with half life constraints, digital therapeutics - alone or in conjunction
21:30 Avoiding unintended consequences of large data, therapeutic creation and delivery - Internal and external regulatory and compliance, third party payer reimbursement for efficacy
31:17 Traditional imaging and biomarkers as endpoints evolving - Decrease variability, identify predictable flaws, assist with resource constraints, identify and test parallel endpoints for future use
36:27 Clinical trials on algorithms - As determined by risk, particularly to address drift and bias
43:30 Pharma contributing to democratized data - Very difficult in competitive environment with current framework, consider regulatory or government driven innovation
55:54 Alpha fold is new and excited to realize utility
57:36 IP and the global marketplace - as cost of sequencing decreases more opportunity and challenges increases, ensure equitable access and development of therapeutics
1:00:59 Final Thoughts From Panelists - Excited to train next gen leaders, global health collaboration, opportunities in bioinformatics and health data, AI is critical for pharma growth